News
2023
September 20, 2023
Brookline Capital Markets Announces Addition of Charles Mather to Investment Banking Team
VIEW PRESS RELEASEJune 28, 2023
Brookline Commends Genelux for Its Recent Issuances
VIEW PRESS RELEASEJune 23, 2023
Calidi Biotherapeutics Receives $25M Series B Commitment Supporting First Light Acquisition Deal
VIEW PRESS RELEASEApril 20, 2023
Brookline Capital Markets' Senior Biotechnology Analyst Kemp Dolliver Discusses Bellerophon Therapeutics and Outlook Therapeutics with Bloomberg BNN
VIEW PRESS RELEASEMarch 17, 2023
Brookline Capital Markets Recognizes the Robust Performance of the Genelux Corporation Initial Public Offering
VIEW PRESS RELEASE2022
December 23, 2022
IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
VIEW PRESS RELEASEDecember 23, 2022
Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
VIEW PRESS RELEASEDecember 7, 2022
X4 Pharmaceuticals Prices $65.0 Million Public Offering
VIEW PRESS RELEASEDecember 7, 2022
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
VIEW PRESS RELEASENovember 30, 2022
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
VIEW PRESS RELEASE2021
August 30, 2021
Ace Global Business Acquisition Limited Announces Pricing of $40 Million Initial Public Offering
VIEW PRESS RELEASEAugust 13, 2021
Jupiter Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
VIEW PRESS RELEASEJuly 7, 2021
Adial Pharmaceuticals Announces $5.0 Million Above Market Private Placement
VIEW PRESS RELEASEJune 22, 2021
Golden Path Acquisition Corp. Announces Pricing of Initial Public Offering
VIEW PRESS RELEASEJune 21, 2021
Creatd Announces Closing of Public Offering of Common Stock
VIEW PRESS RELEASE2020
December 17, 2020
SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
VIEW PRESS RELEASEDecember 16, 2020
BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market
VIEW PRESS RELEASEDecember 14, 2020
BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market
VIEW PRESS RELEASEDecember 11, 2020
9 Meters Biopharma, Inc. Prices Public Offering of Common Stock
VIEW PRESS RELEASENovember 12, 2020
InMed Announces Pricing of US $8.0 Million Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
VIEW PRESS RELEASE2019
December 23, 2019
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
VIEW PRESS RELEASEDecember 12, 2019
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
VIEW PRESS RELEASEOctober 22, 2019
Union Acquisition Corp. II Announces Closing of $200 Million Initial Public Offering
VIEW PRESS RELEASESeptember 26, 2019
Vaxart Announces Pricing of $8 Million Underwritten Public Offering
VIEW PRESS RELEASEAugust 6, 2019
BioCardia Announces Closing of $10.0 Million Public Offering
VIEW PRESS RELEASE